Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
VKTX

Viking Therapeutics (VKTX) stock: insider trades, news & valuation

Net selling
Close · Oct 9, 2026 $28.51 +2.8% on the day -18.5% over 12 months 52-week range $26.29 – $42.13

Share price and insider trades

VKTX closeInsider buyInsider sale
2530354045NovDecJan 2026FebMarAprMayJunJulAugSepOctBought $149,912 on 2026-03-10 · Neil William AubuchonSold $561,760 on 2026-01-02 · Matthew W FoehrSold $1,797,955 on 2025-10-28 · Brian Lian, Greg Zante, Marianna ManciniSold $2,134,200 on 2025-10-27 · Charles A Rowland Jr.Sold $6,268,442 on 2026-07-29 · Brian Lian, Greg Zante, Marianna ManciniSold $11,490,709 on 2026-01-05 · Brian Lian, Greg Zante, Marianna Mancini
Bought, 12 months$150K
Sold, 12 months$22.3M
Insiders buying1
Insiders selling5

Viking Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $150K and 5 sold $22.3M of VKTX stock on the open market.

VKTX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $3.9M sold (4 trades)Q4 2025Q1 2026: $150K bought (1 trades)$150KQ1 2026: $12.1M sold (13 trades)Q1 2026Q2 2026Q3 2026: $6.3M sold (3 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0$6.3M3
Q2 2026—0—0
Q1 2026$150K1$12.1M13
Q4 2025—0$3.9M4

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day1.4×Last 5 sessions
Insiders' paper profit−$22KOn all tracked purchases -14.9%

Summary

Over the past 12 months, 1 Viking Therapeutics, Inc. insider reported open-market purchases totaling $150K, while 5 insiders reported sales totaling $22.3M. 0 of 20 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Jul 29SEC Brian LianCEO, President Sell 148,5172,572,441 held (−5%) $33.32 $4.9M -14.4% —
Jul 29SEC Greg ZanteCFO Sell 21,217212,204 held (−9%) $33.47 $710K -14.8% —
Jul 29SEC Marianna ManciniCOO Sell 18,217422,760 held (−4%) $33.47 $610K -14.8% —
Mar 10SEC Neil William AubuchonChief Commercial Officer Buy 4,475new position $33.50 $150K -14.9% —
Jan 5SEC Brian LianCEO, President Sell 132,4542,600,246 held (−5%) $32.29 $4.3M -11.7% —
Jan 5SEC Brian LianCEO, President Sell 53,2792,546,967 held (−2%) $33.38 $1.8M -14.6% —
Jan 5SEC Brian LianCEO, President Sell 41,2762,505,691 held (−2%) $34.22 $1.4M -16.7% —
Jan 5SEC Greg ZanteCFO Sell 31,961215,571 held (−13%) $32.30 $1.0M -11.7% —
Jan 5SEC Marianna ManciniCOO Sell 31,961434,890 held (−7%) $32.29 $1.0M -11.7% —
Jan 5SEC Matthew W FoehrDirector Sell 16,000132,036 held (−11%) $35.11 $562K -18.8% —
Jan 5SEC Greg ZanteCFO Sell 13,900201,671 held (−6%) $33.38 $464K -14.6% —
Jan 5SEC Marianna ManciniCOO Sell 13,600421,290 held (−3%) $33.37 $454K -14.6% —
Jan 5SEC Marianna ManciniCOO Sell 10,500410,790 held (−2%) $34.22 $359K -16.7% —
Jan 5SEC Greg ZanteCFO Sell 10,300191,371 held (−5%) $34.24 $353K -16.7% —
Jan 5SEC Brian LianCEO, President Sell 6,4002,499,291 held (−0%) $35.07 $224K -18.7% —
Jan 5SEC Marianna ManciniCOO Sell 1,600409,190 held (−0%) $35.07 $56K -18.7% —
Jan 5SEC Greg ZanteCFO Sell 1,500189,891 held (−1%) $32.09 $48K -11.2% —
Oct 28SEC Charles A Rowland Jr.Director Sell 60,00030,000 held (−67%) $35.57 $2.1M -19.8% —
Oct 28SEC Brian LianCEO, President Sell 38,9892,419,109 held (−2%) $35.01 $1.4M -18.6% —
Oct 28SEC Greg ZanteCFO Sell 6,185173,592 held (−3%) $35.00 $216K -18.5% —
Oct 28SEC Marianna ManciniCOO Sell 6,185382,467 held (−2%) $35.00 $216K -18.5% —

Insiders at Viking Therapeutics, Inc.

InsiderBoughtSoldLast filingScore
Brian LianCEO, President — $14.0M Jul 29, 2026 —
Greg ZanteCFO — $2.8M Jul 29, 2026 —
Marianna ManciniCOO — $2.7M Jul 29, 2026 —
Charles A Rowland Jr.Director — $2.1M Oct 28, 2025 —
Matthew W FoehrDirector — $562K Jan 5, 2026 —
Neil William AubuchonChief Commercial Officer $150K — Mar 10, 2026 —

VKTX stock: common questions

Are Viking Therapeutics, Inc. insiders buying VKTX stock?

In the past 12 months, 1 insiders reported open-market purchases of VKTX worth $150K. The latest was Chief Commercial Officer Neil William Aubuchon bought $150K of VKTX at $33.50 — first open-market purchase in our records; opens a new position.

Are Viking Therapeutics, Inc. insiders selling VKTX stock?

5 insiders reported sales worth $22.3M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is VKTX's 52-week range?

Over the past year VKTX has traded between $26.29 and $42.13. It last closed at $28.51 on Oct 9, 2026.